Jubilant Pharmova is currently trading at Rs. 937.65, up by 6.45 points or 0.69% from its previous closing of Rs. 931.20 on the BSE.
The scrip opened at Rs. 931.20 and has touched a high and low of Rs. 942.70 and Rs. 910.00 respectively. So far 4408 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1183.90 on 04-Nov-2025 and a 52 week low of Rs. 783.75 on 10-Mar-2026.
Last one week high and low of the scrip stood at Rs. 1018.75 and Rs. 910.00 respectively. The current market cap of the company is Rs. 14597.32 crore.
The promoters holding in the company stood at 47.68%, while Institutions and Non-Institutions held 28.27% and 24.05% respectively.
Jubilant Pharmova has received approval for issuance of up to 80,000 fully paid-up, rupee denominated, secured / unsecured, listed, rated, redeemable and transferable non-convertible debentures (NCDs) of face value of Rs 1,00,000 each, aggregating up to Rs 800 crore, on a private placement basis, in one or more tranches, subject to applicable laws and regulatory approvals, if any. The Board of Directors of the Company, at its meeting held on October 12, 2026, has, inter alia, considered and approved the same.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
